首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1392014

皮肤癌治疗市场：按药物类型、按癌症类型、按给药途径、按配销通路、按地区

Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2023年11月10日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球皮肤癌药物市场规模预计将从 2023 年的 87.8 亿美元增至 2030 年的 153.2 亿美元，预测期内复合年增长率为 8.3%。

报告范围		报告详情
基准年	2022年	2023年市场规模	87.8亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期复合年增长率	8.30%	2030年市场规模预测	153.2亿美元

图 1. 2023 年按地区分類的皮肤癌药物全球市场占有率(%)

皮肤癌是一种影响皮肤细胞的癌症，是由暴露于紫外线 (UV) 辐射（主要来自阳光或日光浴床）引起的。它是全世界最常见的癌症之一，其发生率逐年上升。为了应对这一日益增长的趋势，製药公司正在专注于皮肤癌治疗的开发和创新。

市场动态：

皮肤癌治疗市场主要是由全球皮肤癌发生率上升所推动的。过度暴露于紫外线、生活方式的改变和高龄化等因素导致这种疾病的盛行率不断上升。此外，治疗性介入的进步和标靶治疗的引入进一步推动了市场的成长。

市场相关人员正在努力获得皮肤癌药物的监管核准，预计这将在预测期内促进全球皮肤癌药物市场的成长。例如，2021年1月，总部位于印度的跨国製药公司Sun Pharma推出了一种「发光二极体」LED光源，用于面部或头皮的轻度至中度厚度的动态治疗（PDT）。联合Levulan Kerastick （氨基乙酰丙酸）盐酸）已获得美国食品药物管理局（美国 FDA）核准。这为患者提供了一种侵入性较小的治疗方法。

然而，也存在一些阻碍市场成长的挑战。高昂的药物开发成本和严格的监管要求是新参与企业的主要障碍。与某些药物相关的副作用和替代治疗方案的可用性是市场成长的抑制因素。

儘管存在这些挑战，市场仍存在一些成长机会。增加对研发（R＆D）活动的投资以及製药公司和研究机构之间的合作预计将推动创新和新治疗方案的推出。此外，对个人化医疗和联合治疗的使用的日益关注提供了市场扩张潜力。

本研究的主要特点

该报告对全球皮肤癌治疗市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球皮肤癌治疗市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的资讯。
全球皮肤癌治疗药物市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球皮肤癌治疗药物市场的各种策略矩阵来促进他们的决策。

介绍
北美洲
美国
加拿大
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
欧洲
德国
英国
西班牙
法国
义大利
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
澳洲
韩国
东南亚国协
其他亚太地区
中东
海湾合作委员会国家
以色列
其他中东地区
非洲
南非
北非
中部非洲

第10章竞争形势

公司简介
Novartis
Merck
Roche
Amgen
Pfizer
Sun Pharma
Bristol-Myers Squibb
AstraZeneca
Johnson & Johnson
Valeant
Daiichi Sankyo
Takeda Pharmaceutical
LEO Pharma
Mylan NV
Sanofi
Regeneron
Eli Lilly
Bayer
Gilead Sciences
Astellas Pharma

第11章章节

参考
调查方法
关于出版商

简介目录

Product Code: CMI6345

Global skin cancer drugs market size is expected to reach US$ 15.32 Bn by 2030, from US$ 8.78 Bn in 2023, at a CAGR of 8.3% during the forecast period.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 8.78 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.30%	2030 Value Projection:	US$ 15.32 Bn

Figure 1. Global Skin Cancer Drugs Market Share (%), By Region, 2023

Skin cancer is a type of cancer that affects the skin cells and is primarily caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. It is one of the most prevalent cancers globally, and its incidence has been increasing over the years. To combat this rising trend, pharmaceutical companies have been focusing on the development and innovation of skin cancer drugs.

Market Dynamics:

The skin cancer drugs market is primarily driven by the rising incidence of skin cancer worldwide. Factors such as excessive exposure to UV radiation, changing lifestyles, and an aging population contribute to the increasing prevalence of the disease. Moreover, advancements in therapeutic interventions and the introduction of targeted therapies have further fueled the market growth.

Market players are engaged in receiving approval from the regulatory authorities for the skin cancer drugs and this is expected to increase the growth of the global skin cancer drugs market, over the forecast period. For instance, in January 2021, Sun Pharma, a India based multinational pharmaceutical company, gained U.S. Food and Drug Administration (U.S. FDA) approval for Levulan Kerastick (aminolevulinic acid HCl) in combination with its "Light Emitting Diode" LED light source for photodynamic therapy (PDT) of minimally to moderately thick actinic keratosis of the face or scalp. It offers patients a less invasive treatment option.

However, there are several challenges that hinder the market growth. High drug development costs and stringent regulatory requirements pose significant barriers for new entrants. Adverse side effects associated with certain drugs and the availability of alternative treatment options act as restraining factors for market growth.

Despite these challenges, the market presents several opportunities for growth. Increasing investments in research and development (R&D) activities, along with collaborations between pharmaceutical companies and research institutions, are expected to drive innovation and the introduction of novel treatment options. Moreover, the growing focus on personalized medicine and the use of combination therapies offer potential avenues for market expansion.

Key features of the study:

This report provides in-depth analysis of the global skin cancer drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global skin cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, Daiichi Sankyo, Takeda Pharmaceutical, LEO Pharma, Mylan N.V., Sanofi, Regeneron, Eli Lilly, Bayer, Gilead Sciences and Astellas Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market

Detailed Segmentation:

By Drug Type
- Chemotherapy Drugs
- Targeted Therapy Drugs
- Immunotherapy Drugs
- Hormone Therapy Drugs
- Others (Photodynamic Therapy, Cryotherapy and Others)
By Cancer Type
- Basal cell carcinoma
- Squamous cell carcinoma
- Melanoma
- Others (Kaposi's sarcoma, Mycosis fungoides and Others)
By Route of Administration
- Topical
- Oral
- Injectable
- Others (Surgical procedures, radiation therapy and Others)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in Global Skin Cancer Drugs Market:
- Novartis
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda Pharmaceutical
- LEO Pharma
- Mylan N.V.
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing incidence of skin cancers
- High costs of targeted therapies
- Combination therapies
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Skin Cancer Drugs Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Hormone Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Photodynamic Therapy, Cryotherapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Basal cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Squamous cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Surgical procedures, radiation therapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Sub-region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2019 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
South Africa
North Africa
Central Africa

10. Competitive Landscape

Company Profile
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck
Roche
Amgen
Pfizer
Sun Pharma
Bristol-Myers Squibb
AstraZeneca
Johnson & Johnson
Valeant
Daiichi Sankyo
Takeda Pharmaceutical
LEO Pharma
Mylan N.V.
Sanofi
Regeneron
Eli Lilly
Bayer
Gilead Sciences
Astellas Pharma
Analyst Views

11. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

皮肤癌治疗市场：按药物类型、按癌症类型、按给药途径、按配销通路、按地区